Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471562 · ClinicalTrials.gov registry record · Phase 1
Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00471562 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 18 participants.
The verdict
NCT00471562, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Angiotensin-(1-7) may stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of angiotensin-(1-7) in treating patients with metastatic or unresectable solid tumors.
Interventions
- BIOLOGICAL therapeutic angiotensin-(1-7)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00471562
The ClinicalTrials.gov registry entry for NCT00471562 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which therapeutic angiotensin-(1-7) is the first listed.
NCT00471562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00471562 about?
NCT00471562 is a clinical study titled "Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors". RATIONALE: Angiotensin-(1-7) may stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of angiotensin-(1-7) in treating patients with metastatic or unresectable solid tumors.
What is the current status of trial NCT00471562?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-03. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00471562?
The interventions under investigation include: therapeutic angiotensin-(1-7) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00471562?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.